Bristol-Myers Squibb (BMY): Roche Study Highlights Increasing Competition - BMO

September 1, 2016 8:51 AM EDT
Get Alerts BMY Hot Sheet
Price: $49.23 -11.28%

Rating Summary:
    10 Buy, 12 Hold, 5 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade BMY Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

BMO Capital analyst, Alex Arfaei, reiterated his Market Perform rating on shares of Bristol-Myers Squibb Co. (NYSE: BMY) after Roche's positive OAK study suggests that the second line NSCLC market will become more competitive. The analyst stated that "This is incrementally negative for BMY's Opdivo, which is dominating in this setting, and probably increases BMY's dependence on combinations".

No change to the price target of $60.

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $57.39 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

BMO Capital

Add Your Comment